Major malaria vaccine trial could save thousands of children
NCT ID NCT04704830
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large-scale study tests the R21/Matrix-M vaccine to prevent malaria in 4,800 children aged 5-36 months living in Africa. The vaccine aims to protect against the most dangerous form of malaria. Researchers will measure how well it works and check for side effects over one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CCVTM, University of Oxford, Churchill Hospital
Oxford, OX3 7LE, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental malaria vaccine aims to block parasite growth
- New hope for the tiniest malaria patients: a safer treatment for infants under 5 kg
- Could a simple device help curb malaria in children?
- New antibody shot shows promise against malaria in early trial
- New 'Star Homes' aim to slash childhood disease in tanzania
- New malaria vaccines show promise in protecting indonesian soldiers